Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arko Corp. (ARKO) vs Quest Diagnostics Inc (DGX) Price & Performance

Arko Corp.Trade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Arko Corp. vs Quest Diagnostics Inc — how do they compare? Arko Corp. trades at $4.49 (market cap $493.06M), while Quest Diagnostics Inc trades at $238.49 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 53.2× Arko Corp.'s market cap, and Arko Corp. pays the higher dividend (2.73%). Which is the better fit depends on your goals.

ARKODGX
Market Cap
$493.06M$26.21B
Sector
Consumer CyclicalHealth
52-Week High
$8.64$238.50
52-Week Low
$3.82$173.49
Enterprise Value
$2.67B$31.97B
Dividend Yield
2.73%1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arko Corp.

ARKO trades at $4.51, down 4.04% amid a bearish technical trend. The stock shows mixed fundamentals: revenue declined to $7.64B in 2025, but net income improved to $22.74M. Recent Q2 2026 earnings missed estimates, with EPS of $0.04 versus $0.15 expected. The company maintains a dividend, paying $0.03 per share semi-annually, and holds a low P/S ratio of 0.06, though the P/E is elevated at 54.94. Analyst sentiment is neutral with all three covering analysts rating it Hold.

Outlook remains cautious due to declining revenue trends and competitive pressures in the convenience store sector. The stock's low price near recent support levels may attract value investors, but risks include volatile fuel margins and high debt. Institutional interest is present, with Dimensional Fund Advisors increasing its stake by 7.3% in Q2 2026.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.

The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arko Corp.

ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.

Read more on ARKO

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX